FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1767-1768 December 2, 1999 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Tazarotene is a novel receptor-selective retinoid originally developed for the topical treatment of mild-to-moderate plaque psoriasis.¹ On the basis of recent hypotheses about the effects of this agent on the differentiation and proliferation of keratinocytes,² we performed an open-label clinical trial to evaluate the efficacy and tolerability of topical tazarotene (0.1 percent in gel) in the treatment of basal-cell carcinoma.

Patients were not eligible for treatment if they had received any therapy for basal-cell carcinoma within four weeks before enrollment in the study. Twenty patients with basal-cell carcinoma (11 men and 9 women; age range, 37 to . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Epstein, E. H., Shepard, J.-A. O., Flotte, T. J. (2008). Case 3-2008 -- An 80-Year-Old Woman with Cutaneous Basal-Cell Carcinomas and Cysts of the Jaws. NEJM 358: 393-401 [Full Text]  
• So, P.-L., Lee, K., Hebert, J., Walker, P., Lu, Y., Hwang, J., Kopelovich, L., Athar, M., Bickers, D., Aszterbaum, M., Epstein, E. H. Jr. (2004). Topical Tazarotene Chemoprevention Reduces Basal Cell Carcinoma Number and Size in Ptch1+/- Mice Exposed to Ultraviolet or Ionizing Radiation. Cancer Res. 64: 4385-4389 [Abstract] [Full Text]  
• Phillips, T. J., Gottlieb, A. B., Leyden, J. J., Lowe, N. J., Lew-Kaya, D. A., Sefton, J., Walker, P. S., Gibson, J. R., and the Tazarotene Cream Photodamage Clinical Stud, (2002). Efficacy of 0.1% Tazarotene Cream for the Treatment of Photodamage: A 12-Month Multicenter, Randomized Trial. Arch Dermatol 138: 1486-1493 [Abstract] [Full Text]  
• Bershad, S., Singer, G. K., Parente, J. E., Tan, M.-H., Sherer, D. W., Persaud, A. N., Lebwohl, M. (2002). Successful Treatment of Acne Vulgaris Using a New Method: Results of a Randomized Vehicle-Controlled Trial of Short-Contact Therapy With 0.1% Tazarotene Gel. Arch Dermatol 138: 481-489 [Abstract] [Full Text]  
• Duvic, M., Helekar, B., Schulz, C., Cho, M., DiSepio, D., Hager, C., DiMao, D., Hazarika, P., Jackson, B., Breuer-McHam, J., Young, J., Clayman, G., Lippman, S. M., Chandraratna, R. A. S., Robinson, N. A., Deucher, A., Eckert, R. L., Nagpal, S. (2000). Expression of a Retinoid-inducible Tumor Suppressor, Tazarotene-inducible Gene-3, Is Decreased in Psoriasis and Skin Cancer. Clin. Cancer Res. 6: 3249-3259 [Abstract] [Full Text]  
• (2000). Tazarotene for Treating Basal-Cell Carcinoma. Journal Watch Dermatology 2000: 9-9 [Full Text]